Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease

Status Enrolling by invitation

Clinical Trial Summary

The investigators propose a study to assess cognitive and developmental outcomes of patients with CLN2 that are untreated and receiving cerliponase alfa. This study aims to validate standardized assessment measures to establish a standard of care. The secondary aim is to compare cognitive and developmental outcomes of patients with CLN2 that are receiving celiponase alfa to a natural history cohort. To accomplish specific aims of the study, the investigators will use a multi-method approach to collect retrospective data collected as standard of care and prospective developmental data in children with CLN2 disease. The investigators will use a combination of standardized measures that include direct assessment and parent report of child development. The investigators focus will also include multiple measures of development including language, motor, social-emotional, and adaptive functioning.

Clinical Trial Description

CLN2 disease is a predominantly late infantile form of neuronal ceroid lipofuscinosis and one of the many genetic isoforms of Batten disease. Mutations in the CLN2 gene are characterized by deficient lysosomal serine protease TPP1, an enzyme that metabolizes intracellular lysosomal storage materials. Accumulations of intracellular deposits occur over time and in many organs of individuals with CLN2 disease and lead to neurodegeneration and, eventually, death. CLN2 disease is an extremely rare genetic disease affecting around 1 per 200,000 live births. Symptoms emerge early in life typically between the ages of 2 and 4 years of age and include seizures, as well as loss of motor, language, and vision functioning. Development further declines in early childhood and by age 6 years, children with CLN2 are often unable to walk or sit unsupported and become blind. The progression of the disease is rapid with death typically occurring in mid-childhood between the ages of 10 and 15 years of age. Recently, enzyme replacement therapy (ERT), cerliponase alfa, which is a recombinant form of human TPPI, was the first FDA-approved treatment to slow the progression of motor decline in children with CLN2. Cerliponase alfa is expected to restore TPP1 enzyme activity in the brain and alter neurodegeneration and disease progression. Animal models suggest promising treatment outcomes as cerliponase alfa significantly delayed the onset of clinical signs, preserved motor and cognitive function, and prolonged life. Initial results from a clinical trial further demonstrated that patients receiving cerliponase alfa had less motor declines, as measured by the CLN2 Clinical Rating Scale, compared to a natural history cohort. Despite these promising results, little is known about the trajectory of other developmental domains, including language, social-emotional, and adaptive functioning of children receiving cerliponase alfa. Likewise, the developmental trajectory of untreated patients with CLN2 is not well understood. Therefore, it is important to understand developmental outcomes and the progression of CLN2 in a natural history cohort in order to compare the effectiveness of treatment outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03862274
Study type	Observational
Source	Nationwide Children's Hospital
Contact
Status	Enrolling by invitation
Phase
Start date	December 1, 2018
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02254863` - UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells	Phase 1
Completed	`NCT01907087` - A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease	Phase 1/Phase 2
Recruiting	`NCT03307304` - Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
Active, not recruiting	`NCT03770572` - Gene Therapy for Children With CLN3 Batten Disease	Phase 1/Phase 2
Recruiting	`NCT06203106` - NYSCF Scientific Discovery Biobank
Completed	`NCT00151268` - Genotype - Phenotype Correlations of LINCL	N/A
Recruiting	`NCT02435940` - Inherited Retinal Degenerative Disease Registry
Completed	`NCT01035424` - Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
Completed	`NCT00151216` - Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis	Phase 1
Active, not recruiting	`NCT04273243` - Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer
Recruiting	`NCT03285425` - Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae
Completed	`NCT00176904` - Stem Cell Transplant for Inborn Errors of Metabolism	Phase 2/Phase 3
Recruiting	`NCT03333200` - Longitudinal Study of Neurodegenerative Disorders
Completed	`NCT02678689` - A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease	Phase 2
Completed	`NCT02485899` - An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease	Phase 1/Phase 2
Active, not recruiting	`NCT05174039` - An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease	Phase 1/Phase 2
Terminated	`NCT01698229` - Collection of Cerebrospinal Fluid in Healthy Children	N/A
Recruiting	`NCT01873924` - Clinical and Neuropsychological Investigations in Batten Disease
Completed	`NCT01161576` - Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)	Phase 1
Recruiting	`NCT04613089` - Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database